CYTOGENETIC TESTING

How Many Of Your Patients Are High risk?*1,2

Cytogenetic testing is an important step in the diagnosis, prognosis, and risk stratification of patients with acute myeloid leukaemia (AML).3,4 It also plays a key role in predicting how well a patient will respond to treatment, helping you shape their therapeutic options3,4

The evolving AML treatment landscape

With a growing number of therapeutic options, making optimal treatment decisions for the individual has become increasingly complex.3
That’s where cytogenetic testing can help4

Learn more with Prof. Nigel Russell

Waiting for cytogenetic test results before assigning stable patients to the most suitable treatment is a reasonable approach5-7

Waiting to receive cytogenetic test results before assigning an intensive therapeutic regimen to clinically stable patients is supported by the outcomes from a study of the relationship between time from diagnosis to treatment (TDT) and prognosis on a large set of real-world data from the AML registry of the Study Alliance Leukemia6

Guidelines recommend selecting treatment according to the patient’s disease and cytogenetic profile3,5,8

Adapted From the Greater Manchester Cancer Haemato-Oncology Pathway: Guidelines for the Management of Acute Myeloid Leukaemia8

flowchart flowchart

This schematic relates to the selection of intensive chemotherapy

Vyxeos Liposomal is indicated for the treatment of adults with newly-diagnosed t-AML or AML-MRC.10 See more here.

Bristol case study:
routine use of cytogenetics

A close professional relationship between the laboratory and clinical team at University Hospitals Bristol NHS Foundation Trust enables the rapid turn around of molecular and cytogenetic test results. It is standard practice at the Trust to wait for and use those results to direct therapy from the beginning, tailoring treatment according to prognostic need

Dr Priyanka Mehta, Dr Rachel Protheroe and Dr Chris Wragg provide an insight into their way of working

Disclaimer: This treatment approach is subject to the physician’s discretion and may depend on the patient’s individual condition and circumstances.

Clinically stable AML patients can wait for cytogenetic test results

Before they are prescribed the optimal treatment for their cancer3-6

Related content

Sign up for the latest news on
Vyxeos Liposomal

Discover more

See the full indication of
Vyxeos Liposomal

Discover more

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

UK-VYX-2100160 l September 2021